Ipsen Biopharmaceuticals, Inc.

450 articles with Ipsen Biopharmaceuticals, Inc.

• Ipsen Delivers Strong 2018 Results and Expects Continued Sales and Profit Growth in 2019

  2/14/2019

  Ipsen, a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2018.

• 

  Top 12 Life Sciences Companies Hiring Now in February

  2/5/2019

  According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!

• Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief

  1/18/2019

  International survey presented at TOXINS 2019 reveals hidden burden of spasticity

• Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019

  1/17/2019

  Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study

• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.

• Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

  1/11/2019

  Ipsen announced that abobotulinumtoxinA (Dysport®) and its recombinant botulinum toxins pipeline are the subject of 50 posters at the 2019 TOXINS International Conference.

• 

  Top 12 Life Sciences Companies Hiring Now in 2019

  1/7/2019

  It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
• 

  Tiburio Launches With $31 Million and Two Compounds From Ipsen Targeting Rare Endocrine Diseases

  1/3/2019

  New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.
• 

  The French Biotech Industry Is Growing, With Focus on R&D and Big Data

  12/28/2018

  For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.
• 

  Top 12 Life Sciences Companies Hiring Now for Candidates Like You

  12/13/2018

  Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
• 

  With New HQ, Ipsen to Rapidly Expand North American Presence

  11/23/2018

  With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.

• Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

  11/20/2018

  Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).

• Ipsen Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

  11/19/2018

  Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

• 

  Top 12 Life Science Companies Hiring Now

  11/2/2018

  Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!

• Ipsen Delivers Strong Sales Growth of 20.2%1 for the Third Quarter of 2018 and Confirms Full Year Guidance

  10/25/2018

  Ipsen today announced sales for the third quarter of 2018.

• Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress

  10/21/2018

  Patients in a real-world setting experienced similar dosing patterns as seen in the pivotal Phase 3 NAPOLI-1 clinical trial

• Health Canada approves XERMELOTM (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)

  10/16/2018

  XERMELO is a first-in-class treatment option for patients whose refractory carcinoid syndrome diarrhea is inadequately controlled with somatostatin analogue (SSA) therapy alone2 

• Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

  10/12/2018

  Ipsen today announced that cabozantinib (Cabometyx®), irinotecan liposome injection (Onivyde®), lanreotide (Somatuline®) and the combination of lanreotide and telotristat (Xermelo®) are the subject of 12 presentations at the 2018 European Society for Medical Oncology (ESMO) annual congress. The meeting takes place in Munich, Germany, October 19-23, 2018.

• Ipsen Canada Appoints Ed Dybka as General Manager

  10/11/2018

  Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dybka as General Manager, effective October 15.

• Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium

  10/5/2018

  Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that seven studies have been selected for poster presentations at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS) taking place in Seattle, Washington, Oct. 4-6, 2018.